Managing comorbidities in idiopathic pulmonary fibrosis

Blair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pul...

Full description

Bibliographic Details
Main Authors: Fulton BG, Ryerson CJ
Format: Article
Language:English
Published: Dove Medical Press 2015-09-01
Series:International Journal of General Medicine
Online Access:https://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM
id doaj-da5a779fe92e40e69c18794b5cb7b366
record_format Article
spelling doaj-da5a779fe92e40e69c18794b5cb7b3662020-11-24T23:36:40ZengDove Medical PressInternational Journal of General Medicine1178-70742015-09-012015default30931823775Managing comorbidities in idiopathic pulmonary fibrosisFulton BGRyerson CJBlair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases. We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning. Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients. Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations. Keywords: interstitial lung disease, management, idiopathic pulmonary fibrosis, comorbiditieshttps://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM
collection DOAJ
language English
format Article
sources DOAJ
author Fulton BG
Ryerson CJ
spellingShingle Fulton BG
Ryerson CJ
Managing comorbidities in idiopathic pulmonary fibrosis
International Journal of General Medicine
author_facet Fulton BG
Ryerson CJ
author_sort Fulton BG
title Managing comorbidities in idiopathic pulmonary fibrosis
title_short Managing comorbidities in idiopathic pulmonary fibrosis
title_full Managing comorbidities in idiopathic pulmonary fibrosis
title_fullStr Managing comorbidities in idiopathic pulmonary fibrosis
title_full_unstemmed Managing comorbidities in idiopathic pulmonary fibrosis
title_sort managing comorbidities in idiopathic pulmonary fibrosis
publisher Dove Medical Press
series International Journal of General Medicine
issn 1178-7074
publishDate 2015-09-01
description Blair G Fulton,1 Christopher J Ryerson1,2 1Department of Medicine, 2Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada Abstract: Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be associated with additional comorbidities through other mechanisms as either a cause or a consequence of these diseases. We review the literature regarding the management of common pulmonary and extra-pulmonary comorbidities, including chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, venous thromboembolism, sleep-disordered breathing, gastroesophageal reflux disease, coronary artery disease, depression and anxiety, and deconditioning. Recent studies have provided some guidance on the management of these diseases in IPF; however, most treatment recommendations are extrapolated from studies of non-IPF patients. Additional studies are required to more accurately determine the clinical features of these comorbidities in patients with IPF and to evaluate conventional treatments and management strategies that are beneficial in non-IPF populations. Keywords: interstitial lung disease, management, idiopathic pulmonary fibrosis, comorbidities
url https://www.dovepress.com/managing-comorbidities-in-idiopathic-pulmonary-fibrosis-peer-reviewed-article-IJGM
work_keys_str_mv AT fultonbg managingcomorbiditiesinidiopathicpulmonaryfibrosis
AT ryersoncj managingcomorbiditiesinidiopathicpulmonaryfibrosis
_version_ 1725522019269738496